Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
Enteropathy-associated T cell lymphoma (EATL) is a rare entity associated with coeliac disease, with a poor prognosis due to perforation and gastro-intestinal bleeding during treatment, and a high relapse risk. Six patients were treated with two cycles of IVE (ifosphamide, etoposide, epirubicin), followed by two cycles of high-dose methotrexate (3 g/m(2)) with folinic acid rescue and a BEAM (carmustine, etoposide, cytarabine, melphalan) autograft. Enteral feeding was given throughout treatment. Four patients remain alive in complete remission at 1.83-4.32 years; two have relapsed. Given the historically poor outcome in these patients, this regimen appears very promising in the treatment of EATL.
Bishton
Mark J
MJ
Department of Haematology, Nottingham City Hospital, Nottingham, UK.
Haynes
Andrew P
AP
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D002446:Celiac Disease / Q000150:complications* / Q000276:immunology / Q000628:therapy; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D004750:Enteral Nutrition; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016411:Lymphoma, T-Cell, Peripheral / Q000150:complications* / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011034:Podophyllotoxin / Q000008:administration & dosage; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D005047:Etoposide; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine; D007069:Ifosfamide; D008727:Methotrexate